Clinical trial
Dopaminergic Therapy for Frontotemporal Dementia Patients: an Interventional, Multi-site, Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of RTG Treatment in Patients with Behavioral FTD
NCT04937452 is registered in ClinicalTrials.gov with I.R.C.C.S. Fondazione Santa Lucia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Dopaminergic Therapy for Frontotemporal Dementia Patients: an Interventional, Multi-site, Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of RTG Treatment in Patients with Behavioral FTD
- Lead sponsor
- I.R.C.C.S. Fondazione Santa Lucia
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 3, 2021
- Completion date
- April 1, 2024
- Enrollment
- 75 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
aphasia, aphasia, primary progressive, brain diseases, central nervous system diseases, communication disorders, dementia, frontotemporal dementia, frontotemporal lobar degeneration, language disorders, mental disorders, metabolic disease, nervous system diseases, neurobehavioral manifestations, neurocognitive disorders, neurodegenerative diseases, neurologic manifestations, pick disease of the brain, proteostasis deficiencies, speech disorders, tdp-43 proteinopathies